Celldex Therapeutics, Inc. (CLDX)
| Market Cap | 1.07B |
| Revenue (ttm) | 4.52M |
| Net Income (ttm) | -48.33M |
| Shares Out | 39.28M |
| EPS (ttm) | -2.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 1 |
| Last Price | $28.01 |
| Previous Close | $27.08 |
| Change ($) | 0.93 |
| Change (%) | 3.43% |
| Day's Open | 27.44 |
| Day's Range | 27.46 - 28.50 |
| Day's Volume | 337,700 |
| 52-Week Range | 1.50 - 29.30 |
--Dermatological indication characterized by chronic, intensely itchy nodules; mast cell activation believed to play an important role in amplifying chronic itch and neuroinflammation-- --Pote...
HAMPTON, N.J., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the Company will participate in a fireside chat at the 10th Annual SVB Leerink Gl...
Celldex Therapeutics is a biopharmaceutical company focused on developing monoclonal and bispecific antibody-based therapeutics. Celldex's new pipeline is now made up of 3 Phase 1 immunotherap...
Investors need to pay close attention to Celldex (CLDX) stock based on the movements in the options market lately.
HAMPTON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the promotion of Freddy A. Jimenez, Esq. to Senior Vice President and General Counsel,...
These stocks have made investors richer by posting explosive revenue growth or advancing significantly in high-impact programs.
The highest performers of the year are biotechs fighting COVID-19 and cancer. Are they still buys for 2021?
HAMPTON, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the first patient has been dosed in its open label clinical trial in cold contact...
HAMPTON, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in a fireside chat at the 3rd Annual Evercore ISI He...
-- A gonist anti-CD40 mAb CDX-1140 demonstrates best-in-class potential; additional expansion cohorts initiated-- --Axl and CDX-527 programs highlighted-- HAMPTON, N.J., Nov. 09, 2020 (GLOBE N...
Celldex (CLDX) delivered earnings and revenue surprises of -5.88% and 130.35%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
HAMPTON, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2020.
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Celldex (CLDX) is developing its monoclonal antibody candidate CDX-0159 as a potential treatment of chronic spontaneous urticaria.
HAMPTON, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened and the first patient has been dosed in its randomized, dou...
Investors need to pay close attention to Celldex Therapeutics (CLDX) stock based on the movements in the options market lately.
HAMPTON, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in Fireside Chats at the Cantor Virtual Global He...
Here we discuss five biotech companies recording impressive growth so far in 2020.
HAMPTON, N.J., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened in its open-label, Phase 1 study of CDX-527 in patients w...
Celldex Therapeutics' (CLDX) CEO Anthony Marucci on Q2 2020 Results - Earnings Call Transcript
--Conference Call and Webcast today at 4:30pm ET-- --Conference Call and Webcast today at 4:30pm ET--
HAMPTON, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will report second quarter 2020 financial results on Thursday, August 6, 2020 after the U.S. financi...
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Momentum Stocks to Buy for July 9th
As of late, it has definitely been a great time to be an investor in Celldex Therapeutics, Inc. (CLDX).
Here's what pushed up shares of the highest-flying healthcare stocks.
The market is reacting to large stock purchases from inside and outside the company.
HAMPTON, N.J., June 18, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the closing of its underwritten public offering of 15...
HAMPTON, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the pricing of its previously announced underwritten ...
HAMPTON, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced that it is proposing to offer and sell, subject to ma...
Celldex Therapeutics Inc (NASDAQ:CLDX) was trading 3% higher from the previous closing price.
Shares of Celldex Therapeutics Inc (NASDAQ:CLDX) moved higher by 1.5% from the previous closing price.
Investors need to pay close attention to Celldex Therapeutics (CLDX) stock based on the movements in the options market lately.
--Data strongly support expanding development into mast cell driven diseases----Data presented in a late-breaking session at EAACI Annual Congress 2020-- HAMPTON, N.J., June 06, 2020 (GLOBE ...
Is (CLDX) Outperforming Other Medical Stocks This Year?
Celldex (CLDX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Celldex also eligible to receive future milestone payments plus royalties Celldex also eligible to receive future milestone payments plus royalties
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock?
CDX-0159 to be studied in chronic idiopathic urticaria after completing healthy volunteer study CDX-0159 to be studied in chronic idiopathic urticaria after completing healthy volunteer study
Celldex (CLDX) reports mixed third-quarter results. Its revenues fall on reduced collaboration and contract revenues.
Celldex (CLDX) delivered earnings and revenue surprises of 10.71% and -56.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
-CDX-0159 IND accepted; Phase 1 study to start by YE 2019- -CDX-527 on track for IND filing in 1H 2020-
-Recommended and maximum tolerated dose defined as 1.5 mg/kg for further study- -Expansion cohort in head and neck squamous cell carcinoma added based on observed clinical activity- -Clinica...
HAMPTON, N.J., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that multiple Company drug development programs will be the subject of presentations...
HAMPTON, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, and Tibor ...
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock?
Celldex (CLDX) reports mixed second-quarter results. Revenues fall on reduced collaboration and contract revenues.
About CLDX
Celldex Therapeutics, a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. It develops CDX-1140, an agonist human monoclonal antibody, which is being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in metastatic solid tumors and B cell lymphomas; CDX-3379, a monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Er... [Read more...]
| Industry Biotechnology | IPO Date Mar 10, 2008 |
| CEO Anthony Marucci | Employees 127 |
| Stock Exchange NASDAQ | Ticker Symbol CLDX |
Financial Performance
In 2019, CLDX's revenue was $3.57 million, a decrease of -62.54% compared to the previous year's $9.54 million. Losses were -$50.88 million, -66.35% less than in 2018.
Analyst Forecasts
According to 3 analysts, the average rating for CLDX stock is "Strong Buy." The 12-month stock price forecast is 30.67, which is an increase of 9.50% from the latest price.